The flavonoid hesperetin alleviates behavioral abnormality in 6-hydroxydopamine rat model of hemi-parkinsonism

Basic and Clinical Neuroscience

Volumn 2, Issue 1, 2010, Pages 20-23

  Baluchnejadmojarad, Tourandokht ^a   Roghani, Mehrdad ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHED UNIVERSITY   (Iran)

Author keywords

6 hydroxydopamine; Hesperetin; Parkinson's disease; Rotational behavior

Indexed keywords

HESPERETIN; OXIDOPAMINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; CIRCLING BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; RAT;

EID: 84902688160     PISSN: 2008126X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Algeri S. (2002). A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes. Neurobiol Aging, 237, 19-35.
2. Baluchnejadmojarad T, Roghani M, Nadoushan MR, Bagheri M. (2009). Neuroprotective effect of genistein in 6-hydroxydopamine Hemi-parkinsonian rat model. Phytother.Res, 23, 132-135.
3. Bezard E, Brotchie JM, Gross CE. (2001). Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci. 2, 577-588.
4. Choi EJ, Ahn WS. (2008). Neuroprotective effects of chronic hesperetin administration in mice. Arch Pharm Res. 2008 Nov;31(11),1457-62. Epub Nov 21.
5. Dauer W, Przedborski S. (2003). Parkinson's disease: mechanisms and models. Neuron; 39, 889-909.
6. Foley P, Riederer P. (2000). Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease. J Neurol; 247, 82-94.
7. Maher P. A comparison of the neurotrophic activities of the flavonoid fisetin and some of its derivatives. Free Radic Res 2006; 40, 1105-11.
8. Paxinos G, Watson C. (1986). The rat brain in stereotaxic coordinates, 2nd ed., Academic Press, San Diego.
9. Roghani M, Behzadi G. (2001). Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. Brain Res; 892, 211-7.
10. Sauer H, Oertel WH. (1994). Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neurosci; 59, 401-415.
11. Schwarting RK, Huston JP. (1997). Behavioral and neurochemical dynamics of neurotoxic meso-striatal dopamine lesions. Neurotoxicol; 18, 689-708.
12. Vauzour D, Ravaioli G, Vafeiadou K, Rodriguez-Mateos A, Angeloni C, Spencer JP. (2008). Peroxynitrite induced formation of the neurotoxins 5-S-cysteinyl-dopamine and DHBT-1: Implications for Parkinson's disease and protection by polyphenols. Arch Biochem Biophys; 476, 145-51.
13. Wu SS, Frucht SJ. (2005). Treatment of Parkinson's disease: what's on the horizon? CNS Drugs; 19, 723-43.
14. Yao Y, Vieira A. (2007). Protective activities of Vaccinium antioxidants with potential relevance to mitochondrial dysfunction and neurotoxicity. Neurotoxicology, 28, 93-100.